Press Releases :: BiomX, Inc. (PHGE)

Mar 06, 2024 7:30am EST

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Jan 04, 2024 8:00am EST

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

Nov 30, 2023 4:15pm EST

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Nov 29, 2023 6:30am EST

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Nov 14, 2023 6:30am EST

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 27, 2023 8:00am EDT

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

Oct 18, 2023 8:00am EDT

BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

Oct 04, 2023 6:34am EDT

BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Sep 07, 2023 9:00am EDT

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023

Sep 06, 2023 4:05pm EDT

BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference

Previous
1
2
3
4
5
6
7
8
9
10
…13
Next

Investor Contact Information

Company

BiomX, Inc.
708 Quince Orchard Rd
Suite 205
Gaithersburg, MD 20878
USA
info@biomx.com

Investor Relations

Ben Cohen
benc@biomx.com